Enhanced Vector Bioprocessing Technologies for Cell and Gene Therapies

Viruses are being turned into microscopic delivery trucks to fix faulty genes inside human cells, but manufacturing enough of them for widespread patient use remains prohibitively expensive. This project tackles that bottleneck by developing new production methods to churn out large quantities of therapeutic viruses at a fraction of the current cost. Cell and gene therapies have already shown they can treat certain cancers and inherited disorders, but their high price tag—often hundreds of thousands of pounds per patient—limits access to a few hundred people a year. If these new bioprocessing technologies succeed, they could slash manufacturing costs and scale up supply, making these therapies a routine option rather than a last resort. The work is not about discovering a new drug; it is about fixing the industrial infrastructure that quietly determines whether a proven treatment ever reaches patients. Synpromics, a synthetic biology company in Edinburgh, and the Cell Therapy Catapult are collaborating to turn a lab-scale process into a commercially viable manufacturing line. The result could be cheaper, faster, and more reliable virus production that underpins an entire generation of gene-based medicines.